IDH1 and central nervous system cancer: The scope of this analysis was to uncover the mechanisms that explain the action of the mutant IDH1 inhibitors in glioma patients, and determine a comprehensive panel of imaging biomarkers that can be used to objectively assess the response to mutant IDH1 inhibition.